Petosemtamab

Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.

Merus will present updated interim Phase 2 data on petosemtamab combined with pembrolizumab for first-line treatment of PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma at the 2025 ASCO Annual Meeting.

Merus N.V.'s petosemtamab receives FDA Breakthrough Therapy designation for first-line treatment of PD-L1 positive head and neck cancer when combined with pembrolizumab.

Merus N.V. has initiated a Phase 2 clinical trial of petosemtamab as a monotherapy for patients with heavily pretreated (3L+) metastatic colorectal cancer (mCRC).

Merus' petosemtamab demonstrates a 42.5% overall response rate in Phase 2 trials for second-line or higher head and neck squamous cell carcinoma (HNSCC).